30 March 2015
Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/3h4dtIexB8k/150330122449.htm
